Skip to main content

Sana Biotechnology, Inc.

SANA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001770121

No open-market purchases or sales by Sana Biotechnology, Inc. insiders were filed in the last 90 days; 211 institutions reported holding it in 13F filings for Q2 2026, worth $644.7M in total; no superinvestor holds it.

Holders of 5% or more of SANA

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Sana Biotechnology, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of SANA
HolderLatest formStakeChangeFirst filedLatest filingFiling
ARCH Venture Fund IX, L.P.13G/A17.30%46.1M shares–Nov 14, 20251 filingNov 14, 2025SEC
Ra Capital Management, L.P.13G6.30%18.8M sharesNewMay 21, 20261 filingMay 21, 2026SEC
BlackRock, Inc.13G5.10%13.6M shares+0.20 ppfrom 4.90%Apr 25, 20252 filingsJan 21, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

5 Schedule 13D and 13G filings on Sana Biotechnology, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on SANA
Filed (ET)FilerFormStakeChangeEvent dateFiling
May 21, 20269:12 PM ETRa Capital Management, L.P.and 3 others13G6.30%18.8M sharesNewMay 14, 2026SEC
Jan 21, 202612:30 PM ETBlackRock, Inc.13G5.10%13.6M shares+0.20 ppfrom 4.90%Dec 31, 2025SEC
Nov 14, 20254:30 PM ETARCH Venture Fund IX, L.P.and 14 others13G/A17.30%46.1M shares–Sep 30, 2025SEC
Apr 25, 20251:00 PM ETBlackRock, Inc.13G/A4.90%11.0M shares–Below 5%Mar 31, 2025SEC
Jan 31, 20259:54 AM ETVanguard Group Inc13G/A4.81%10.7M shares–Below 5%Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Sana Biotechnology, Inc. shares.

No Form 144 notices for Sana Biotechnology, Inc. are on file.